The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
111
Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
City of Saint Peters, Missouri, United States
Pfizer Investigational Site
Overall confirmed objective response rate (ORR)
Time frame: From screening until at least 28 days beyond discontinuation of study treatment.
Progression-free survival (PFS)
Time frame: From screening until disease progression or discontinuation of study
Time to progression (TTP)
Time frame: From screening until disease progression or discontinuation of study
Duration of response (DR)
Time frame: From screening until disease progression or discontinuation of study
Overall survival (OS)
Time frame: From screening until disease progression or discontinuation of study
Probability of survival at 1 year
Time frame: From screening until disease progression or discontinuation of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Chapel Hill, North Carolina, United States
Pfizer Investigational Site
Clinton, North Carolina, United States
Pfizer Investigational Site
Goldsboro, North Carolina, United States
Pfizer Investigational Site
Pollocksville, North Carolina, United States
Pfizer Investigational Site
Wilson, North Carolina, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
...and 4 more locations